Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Cash & Equivalents: 2015-2024

Historic Cash & Equivalents for Wave Life Sciences (WVE) over the last 10 years, with Dec 2024 value amounting to $302.1 million.

  • Wave Life Sciences' Cash & Equivalents fell 36.90% to $196.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $196.2 million, marking a year-over-year decrease of 36.90%. This contributed to the annual value of $302.1 million for FY2024, which is 50.77% up from last year.
  • Latest data reveals that Wave Life Sciences reported Cash & Equivalents of $302.1 million as of FY2024, which was up 50.77% from $200.4 million recorded in FY2023.
  • In the past 5 years, Wave Life Sciences' Cash & Equivalents ranged from a high of $302.1 million in FY2024 and a low of $88.5 million during FY2022.
  • For the 3-year period, Wave Life Sciences' Cash & Equivalents averaged around $197.0 million, with its median value being $200.4 million (2023).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first tumbled by 41.22% in 2022, then skyrocketed by 126.39% in 2023.
  • Yearly analysis of 5 years shows Wave Life Sciences' Cash & Equivalents stood at $184.5 million in 2020, then decreased by 18.39% to $150.6 million in 2021, then tumbled by 41.22% to $88.5 million in 2022, then soared by 126.39% to $200.4 million in 2023, then skyrocketed by 50.77% to $302.1 million in 2024.